ArticleScientific reports2017
Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Mycobacterium avium infection induced PD-L1 overexpression in macrophages: a potential involvement with immune escape.Cell death & disease · 2026Article
- Association between immunity and antimicrobial treatment resistance in patients with Mycobacterium avium complex pulmonary disease: a multicenter observational study.BMC infectious diseases · 2025Observational
- A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?Journal of thoracic disease · 2024Review
- Risk factors for microbiological persistence after 6 months of treatment forMicrobiology spectrum · 2023Article
- Prevalence of Latent Tuberculous Infection in Patients With Nontuberculous Mycobacterial Lung Disease and Colonization: A Prospective Study in an Intermediate Tuberculosis Burden Country.Open forum infectious diseases · 2022Article
- Characterizing and correcting immune dysfunction in non-tuberculous mycobacterial disease.Frontiers in immunology · 2022Article
- Characterization of natural killer and T cells in bronchoalveolar lavage and peripheral blood of sarcoidosis patients.Frontiers in immunology · 2022Article
- Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review.Frontiers in immunology · 2022Review
- T-Cell Exhaustion inMicroorganisms · 2021Review
- Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease.Microorganisms · 2021Review
- Exploring Potential COPD Immunosuppression Pathways Causing Increased Susceptibility for MAC Infections among COPD Patients.Clinics and practice · 2021Review
- Non-tuberculous mycobacteria immunopathogenesis: Closer than they appear. a prime of innate immunity trade-off and NTM ways into virulence.Scandinavian journal of immunology · 2021Review
- Article
- The Trend of TIM3 Expression on T Cells in Patients With Nontuberculous Mycobacterial Lung Disease: From Immune Cell Dysfunction to Clinical Severity.Frontiers in immunology · 2021Article
- Characteristics of Circulating CD4Journal of clinical medicine · 2020Article
- Invasive Tracheobronchial Aspergillosis with Bronchial Ulcers Complicated by Nontuberculous Mycobacterial Disease.Internal medicine (Tokyo, Japan) · 2020Article
- Looking beyond Typical Treatments for Atypical Mycobacteria.Antibiotics (Basel, Switzerland) · 2020Review
- The New Frontier of Host-Directed Therapies forFrontiers in immunology · 2020Review
- The Rise of Non-Tuberculosis Mycobacterial Lung Disease.Frontiers in immunology · 2020Review
- The Clinical Significance of Programmed Death-1, Regulatory T Cells and Myeloid Derived Suppressor Cells in Patients with Nontuberculous Mycobacteria-Lung Disease.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium avium complex-induced lung disease (MAC-LD) becomes important due to its increasing prevalence. Attenuated cellular immunity associated with programmed cell death (PD)-1 may play a pathophysiological role in MAC-LD but lacks of investigation. We enrolled 80 participants in this prospective study, including 50 with MAC-LD and 30 healthy controls. Peripheral blood mononuclear cells (PBMCs), lymphocytes and monocyte-derived macrophages were used for MAC antigen stimulation. Patients with MAC-LD had lower tumor necrosis factor-α and interferon-γ responses compared to the healthy controls in PBMC stimulation assays with MAC bacilli. These responses improved after MAC treatment. The PD-1 and PD ligand expressions and apoptosis were higher in the lymphocytes of the patients with MAC-LD compared to the controls. Both PD-1 and apoptosis on T lymphocytes were significantly increased in the patients with MAC-LD, either by direct MAC stimulation or by MAC-primed macrophage activation. Partially blocking PD-1 and the PD ligand with antagonizing antibodies in the stimulation assay significantly increased the cytokine production of IFN-γ and decreased the apoptosis on T lymphocytes. In conclusion, the patients with MAC-LD have attenuated lymphocyte immunity, which might be associated with increasing activation of PD-1 and PD-1 ligand. Regulating such activation might improve the lymphocytic secretion of IFN-γ and reduce apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.